These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 10123232)

  • 1. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(105):37988-98. PubMed ID: 12049094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of regulations regarding certification of antibiotic drugs; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(91):26127-9. PubMed ID: 10179335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal of regulations regarding certification of antibiotic drugs--FDA. Direct final rule.
    Fed Regist; 1998 May; 63(91):26066-9. PubMed ID: 10179333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
    Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial disclosure by clinical investigators--FDA. Final rule.
    Fed Regist; 1998 Feb; 63(21):5233-54. PubMed ID: 10177332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated approval of oncology products: a decade of experience.
    Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
    J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
    Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
    Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.